I had just the opposite impression. In fact, I was thinking the FDA ought to have paid to pitch that interview to Tucker, rather than Humanigen.
Tucker gave Durrant two chances to unload on the FDA. First, he asked Durrant what kind of therapy is this that hasn't received the OK from the FDA, and why does Durrant think that is? And then Tucker wanted to know why the FDA (government) hasn't used their resources to push this product.
I think Durrant was very pro-FDA in his response. They have a difficult job, they're very stretched and under-resourced. They just need additional data, and the FDA and Humanigen are working as collaborative partners.
That just tells me that US approval is on-tap.